Lili Du

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Lajos Pusztai, Christina Yau, Denise M. Wolf et al. · Cancer Cell · 2021 · 300 citations · Full text

I-spy2 Trial, Breast Oncology, Medicine +7

BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling

Harina Vin, Sandra S. Ojeda, Grace Ching et al. · eLife · 2013 · 80 citations · Full text

Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity

Charles H. Adelmann, Grace Ching, Lili Du et al. · Oncotarget · 2016 · 61 citations · Full text

The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues

Michał Marczyk, Chunxiao Fu, Rosanna Lau et al. · BMC Cancer · 2019 · 56 citations · Full text

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Lili Du, Christina Yau, Lamorna Brown Swigart et al. · Annals of Oncology · 2021 · 45 citations · Full text

Chemo-endocrine Therapy, Breast Oncology, Medicine +8